Table 2 The proportion of participants with simultaneous positive responses to ≥2 cytokines

From: Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

 

LZ901 group n/N (%)

HZ/su group n/N(%)

Difference % (95% CI) (LZ901 vs. HZ/su)

p value

The proportion of CD42+ T-cell responders

 All age

117/141 (83.0)

79/136 (58.1)

24.9 (14.5,35.3)

<0.0001

 50–59 years

57/73 (78.1)

42/73 (57.5)

20.6 (5.8,34.5)

<0.0001

 60–69 years

47/52 (90.4)

29/50 (58.0)

32.4 (12.6,52.2)

<0.0001

 ≥70 years

13/16 (81.3)

8/13 (61.5)

32.6 (−12.9,52.3)

0.03719

The proportion of CD82+ T-cell responders

All age

66/141 (46.8)

12/136 (8.8)

38.0 (28.5,47.5)

<0.0001

50–59 years

36/73 (49.3)

4/73 (5.5)

43.8 (31.2,56.5)

<0.0001

60–69 years

22/52 (42.3)

6/50 (12.0)

30.3 (14.1,46.5)

<0.0001

≥70 years

8/16 (50.0)

2/13 (15.4)

34.6 (3.2,66.0)

0.00267

  1. N = the number of participants included in the analysis; n = the number of participants with simultaneous positive responses to ≥2 cytokines (referred to as gE-specific CD42+/CD82+ T-cell responses; For each cytokine (IFN-γ, IL-2, TNF-α, or CD40L), a positive responder was defined as a 2-fold increase in cytokine-secreting T cells post-vaccination compared to pre-vaccination levels. In HZ/su group, there was one sample from each of 50–59 years and 60–69 years group that could not be tested due to insufficient cell quantity; 95% CIs of the rate difference were calculated using the Miettinen and Nurminen method, two-sided χ2 test or Fisher’s exact test was used for comparisons between two groups.
Back to article page